Printer Friendly

BIORELEASE CORP. NAMES DR. R. BRUCE REEVES CEO AND PRESIDENT

 SALEM, N.H., June 22 /PRNewswire/ -- Biorelease Corp. (NASDAQ: BREL) today announced that Dr. R. Bruce Reeves has been named chief executive officer and president. Since 1989, Dr. Reeves has devoted full-time to Biorelease Corp. and its subsidiaries, serving most recently as executive vice president, chief operating officer and secretary for Biorelease Corp. as well as president of the company's operating subsidiary Biorelease Technologies, Inc. Dr. Reeves will continue to serve as a director for Biorelease Corp., a position he has held since 1989.
 "Dr. Reeves' leadership and business acumen has guided Biorelease through its evolution into a viable biotechnology company," said Richard Schubert, chairman of the board for Biorelease Corp. "Bruce has initiated a sound fiscal strategy for Biorelease -- offsetting a portion of the company's long-term pharmaceutical development expenses through potential revenues from our first product, Erythrogen(tm)."
 Dr. Reeves has more than 23 years of business management experience, primarily in entrepreneurial and start-up ventures. He has more than 10 years experience in high technology and new product development, including five years with General Electric Company in various business development operations. Prior to joining Biorelease, Dr. Reeves was chief executive officer of a closely held New Hampshire-based real estate management and development company. Dr. Reeves received a Ph.D. in Chemistry from The Johns Hopkins University.
 Dr. Reeves succeeds Dr. P. Calvin Maybury as chief executive officer and president of the company. Dr. Maybury will continue to serve as a director for Biorelease Corp.
 "Cal Maybury's pharmaceutical research expertise has proven invaluable in creating a research and development organization and strategy for Biorelease, and we look forward to his continued input as the company moves its other products closer toward commercialization," Schubert added.
 Biorelease Corp. is dedicated to commercializing proprietary cell- culture additives and developing pharmaceutical applications of its hemoglobin-based and chondroitin sulfate-based carrier technologies. The company is headquartered in Salem, N.H.
 -0- 6/22/93
 /CONTACT: R. Bruce Reeves, Ph.D., CEO and president of Biorelease Corp., 603-893-7300; or Christopher Taylor of Feinstein Partners Inc., 617-577-8110, for Biorelease/
 (BREL)


CO: Biorelease Corp. ST: New Hampshire IN: MTC SU: PER

DH -- NE004 -- 4449 06/22/93 09:42 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 22, 1993
Words:361
Previous Article:BRADLEES, INC. REPORTS FIRST QUARTER RESULTS
Next Article:SOLECTRON INTENDS TO BUY PHILIP'S SCOTTISH CONTRACT ASSEMBLY BUSINESS
Topics:


Related Articles
OIA, INC. ENTERS NASDAQ SYSTEM
BIORELEASE ESTABLISHES CELL CULTURE PRODUCTS DIVISION AND IS FINALIZING PLANS FOR COMMERCIAL LAUNCH OF ERYTHROGEN
NOTED BLOOD SUBSTITUTE RESEARCHER JOINS BIORELEASE CORP.
Biorelease Terminates Planned Merger with TheraMed, Names Gauci as President of BTI
Bruce Sachs Named to Vertex Board of Directors.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters